TOP-5 studies on disease treatment from 25.10.2026 - 01.11.2026
The future of metabolic and bariatric surgery in the era of glucagon-like peptide-1: has the scalpel become outdated?; The metabolic axis of the brain: GLP-1 signals, insulin resistance, and pharmacotherapy for obesity in neurodegeneration; Urological manifestations in obesity; β-hydroxybutyrate in cancer: from alternative fuel to context-dependent metabolic signal; New roles of ETV4 in remodeling the tumor microenvironment: mechanisms and therapeutic targeting.
5. The future of metabolic and bariatric surgery in the era of glucagon-like peptide-1: has the scalpel become outdated?
About the work.
The evolution of metabolic and bariatric surgery (MBS) is examined in the context of the use of glucagon-like peptide-1 (GLP-1) receptor agonists. The advantages and disadvantages of MBS compared to pharmacological treatment of obesity are discussed.
Results.
New data show that MBS provides a more significant and sustained weight loss compared to the use of GLP-1 RA alone. MBS and GLP-1 RA may be complementary methods in the individualized treatment of obesity.
4. The metabolic axis of the brain: GLP-1 signals, insulin resistance, and pharmacotherapy for obesity in neurodegeneration.
About the work.
The study aims to explore the relationship between metabolic diseases and neurodegeneration, focusing on the role of GLP-1 receptor activating agents in the treatment of diseases such as Alzheimer's and Parkinson's disease.
Results.
Both key phase 3 clinical trials did not demonstrate statistically significant advantages in primary clinical outcomes, despite favorable biomarker and epidemiological signals.
3. Urological manifestations in obesity.
About the work.
The review focuses on the impact of obesity on various urological conditions, including cancer, infections, kidney stones, and men's health. Recent data on how obesity affects these diseases and what approaches can be used for their management are discussed.
Results.
Obesity is associated with a paradoxical survival benefit in kidney cancer patients but contributes to aggressive prostate cancer. Obesity increases the risk of kidney stone formation, and GLP-1 medications and SGLT-2 inhibitors have different effects on lithogenesis and urinary tract infections. Obesity is a modifiable risk factor for overactive bladder and stress urinary incontinence, which improve with weight loss.
2. β-hydroxybutyrate in cancer: from alternative fuel to context-dependent metabolic signal.
About the work.
The role of β-hydroxybutyrate (BHB) in cancer is investigated, including its influence on tumor cell metabolism and the immune microenvironment. Various contexts in which BHB can either inhibit or promote tumor growth are discussed.
Results.
BHB demonstrates high contextual dependence in its biological effects on cancer; in some models, it inhibits inflammation and tumor growth, while in others, it promotes survival and metastasis. The effectiveness of using BHB depends on the ability of tumor cells to undergo ketolysis and the distribution of cells in the tumor microenvironment.